Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms

Lisa Xingguang Lee,Ping Zhou,Cindy Varga,Teresa Fogaren,Katelynn Ho,Xun Ma,Melissa Warner,Denis Toskic,Adin Kugelmass,Raymond L. Comenzo

Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms

2019

Lisa Xingguang Lee
Ping Zhou
Cindy Varga
Teresa Fogaren
Katelynn Ho
Xun Ma
Melissa Warner
Denis Toskic
Adin Kugelmass
Raymond L. Comenzo

In systemic AL amyloidosis treatment targeting the clonal plasma cells that produce the pathologic free light chain (FLC) can achieve FLC normalization, organ responses and improved survival. Howev...

Keywords:

Refractory
Immunology
Daratumumab
AL amyloidosis
Biochemistry
Diabetes mellitus
Medicine
Receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations